Skip to main content

Table 1 Inclusion and exclusion criteria for IMPRESSION study

From: Influence of Morphine on Pharmacokinetics and Pharmacodynamics of Ticagrelor in Patients with Acute Myocardial Infarction (IMPRESSION): study protocol for a randomized controlled trial

Inclusion Criteria
Provision of informed consent prior to any study-specific procedures Provision of informed consent for angiography and PCI
Diagnosis of acute STEMI or acute NSTEMI Male or non-pregnant female, aged 18 to 80 years old
Exclusion Criteria
Chest pain described by the patient as unbearable or patient’s request for analgesics History of major surgery or severe trauma (within 3 months)
Prior morphine administration during the current STEMI or NSTEMI Patients considered by the investigator to be at risk of bradycardic events
Treatment with ticlopidine, clopidogrel, prasugrel, or ticagrelor within 14 days before the study enrollment Second- or third-degree atrioventricular block during screening for eligibility
Hypersensitivity to ticagrelor Patient required dialysis
Current treatment with oral anticoagulant or chronic therapy with LMWH History of asthma or severe chronic obstructive pulmonary disease
Active bleeding Manifest infection or inflammatory state
History of intracranial hemorrhage Killip class III or IV during screening for eligibility
Recent gastrointestinal bleeding (within 30 days) Respiratory failure
History of coagulation disorders History of severe chronic heart failure (NYHA class III or IV)
Concomitant therapy with strong CYP3A inducers (rifampicin, phenytoin, carbamazepine, dexamethasone, phenobarbital) within 14 days and during study treatment Concomitant therapy with strong CYP3A inhibitors (ketoconazole, itraconazole, voriconazole, telithromycin, clarithromycin, nefazadone, ritonavir, saquinavir, nelfinavir, indinavir, atazanavir)
Hemoglobin concentration less than 10.0 g/dl Platelet count less than <100 x10^3/mcl
History of moderate or severe hepatic impairment Body weight below 50 kg
  1. LMWH: low-molecular-weight heparin; NSTEMI: non-ST-segment elevation myocardial infarction; NYHA: New York Heart Association; PCI: percutaneous coronary intervention; STEMI: ST-segment elevation myocardial infarction.